Corrigendum

Corrigendum to ‘ESPEN guideline: Clinical nutrition in inflammatory bowel disease’ [Clinical Nutrition 36 (2) (2016) 321–347]

Alastair Forbes a,*, Johanna Escher b, Xavier Hébuterne c, Stanislaw Klęk d, Zeljko Krznaric e, Stéphane Schneider c, Raanan Shamir f, Kalina Starelova g, Nicolette Wierdsmah, Anthony E. Wiskini, Stephan C. Bischoff j

a Norwich Medical School, University of East Anglia, Bob Champion Building, James Watson Road, Norwich, NR4 7UQ, United Kingdom
b Erasmus Medical Center e Sophia Children’s Hospital, Office Sp-3460, Wyremaveg 80, 3015 CN, Rotterdam, the Netherlands
c Gastroenterologie et Nutrition Clinique, CHU de Nice, Université Cote d’Azur, Nice, France
d General and Oncology Surgery Unit, Stanley Dudrick’s Memorial Hospital, 15 Tyniecka Street, 32-050, Skawina, Krakau, Poland
e Clinical Hospital Centre Zagreb, University of Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia
f Tel-Aviv University, Schneider Children’s Medical Center of Israel, 34 Kaplan St., Petach-Tikva, 49202, Israel
gh University Clinic for Gastroenterohepatology, Clinical Centre “Mother Therese”, Mother Therese Str No 18, Skopje, Macedonia
i VU University Medical Center, Department of Nutrition and Dietetics, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
j Paediatric Gastroenterology & Nutrition Unit, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, United Kingdom
k Institut für Ernährungsmedizin (180) Universität Hohenheim, Fruwirthstr. 12, 70593 Stuttgart, Germany

The recommendations 14A, 32A, 33A, and 33B, which recommend “VSL#3”, refer only to the probiotic product used in the cited literature and equivalent products independent from the present product labeling.

The authors would like to apologise for any inconvenience caused.

* Corresponding author.
E-mail address: alastair.forbes@uea.ac.uk (A. Forbes).